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line were observed during 18-month treatment with risperidone
long-acting injection in patients with schizophrenia.
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OBJECTIVE: Olanzapine and clozapine are two atypical antip-
sychotics associated with high risk of developing diabetes melli-
tus. However, a head to head comparison between these two
medications is not available. The objective of our study is to
compare the risk of developing type II diabetes with the use of
olanzapine vs. clozapine. METHODS: The study was a retro-
spective, longitudinal cohort analysis using 2001 Georgia
Medicaid claims data. Patients who had psychosis (ICD-CM-9:
290.xx–299.xx) and had received at least one prescription of
olanzapine or clozapine from March through November were
identiﬁed. The two study groups were deﬁned as patients who
initiated new treatment episodes of olanzapine and clozapine
after a 60 days window free of these medications. Patients who
received diabetes diagnosis (ICD-CM-9: 250.x0–250.x2) or
antidiabetic prescriptions 60 days prior and 30 days post the
index date (the date of treatment initiation) were regarded as
having pre-existing diabetes and excluded from the study. Logis-
tic regression analysis was employed to assess the association
between newly developed diabetes mellitus and the use of
antipsychotics. Confounders such as age, gender, race, treatment
duration, use of other antipyschotics, use of beta blockers and
thiazide diuretics were included in the ﬁnal model. RESULTS:
Out of 18,373 patients with an antipsychotic prescription in
2001, 4934 patients were olanzapine users and 376 patients were
clozapine users. The incidence rate of type 2 diabetes was 1.05%
among olanzapine users and 0.21% among clozapine users. After
controlling the confounders, it was found that the risk of devel-
oping type 2 diabetes was signiﬁcantly less for olanzapine
users as compared to clozapine users (OR 0.346 [CI 0.18–0.67]).
CONCLUSION: Patients taking clozapine are associated with
greater risk of developing type II diabetes as compared to
patients taking olanzapine.
PMH15
ANALYSIS OF POTENTIAL DRUG-DRUG INTERACTION PAIRS
ASSOCIATEDWITH ANTIPSYCHOTICS AMONG MEDICAID
PATIENTSWITH SCHIZOPHRENIA OR BIPOLAR DISORDER
Jing Y1, Guo JJ1, Patel NC2, Kelton CM1, Fan H3, Keck P1
1University of Cincinnati, Cincinnati, OH, USA, 2University of Georgia,
Augusta, GA, USA, 3Covance Inc, Sun Prairie,WI, USA
OBJECTIVE: Since many antipsychotics are metabolized by
cytochrome P450 (CYP450) isoenzymes (1A2, 2D6, and 3A4),
we proposed to assess the risk of receiving potential drug-drug
interaction (DDI) pairs associated with the inhibition or induc-
tion of CYP450 isoenzymes. METHODS: Using the Ohio Med-
icaid claims database from January 1, 2001 to December 31,
2003, a total of 44,511 patients (18  age  65) with a schizo-
phrenia or bipolar disorder diagnosis and receiving at least one
study antipsychotic were selected for this study. Any clinically
signiﬁcant (moderate or severe) DDI pair was deﬁned to have
concomitant exposure if any of the days supply for an antipsy-
chotic prescription overlapped with the days supply of an
interacting medication by at least one day. Patients with schizo-
phrenia and bipolar disorder were analyzed separately. Multi-
variable logistic regression analysis was used to assess risk factors
associated with the receipt of a potential DDI pair. RESULTS: Of
the 44,511 study patients, potential DDI pairs were received by
12.1% (11.9% in schizophrenia, 12.9% in schizoaffective, and
11.8% in bipolar sub-cohorts) as same-day prescriptions dis-
pensed and by 24.5% (24.7% in schizophrenia, 26.5% in
schizoaffective, and 24.5% in bipolar sub-cohorts) as prescrip-
tions with at least a one-day overlap. The most frequent DDI
pairs were observed with olanzapine (45.0%), risperidone
(23.5%), and quetiapine (13.4%). A higher risk of receiving a
potential DDI pair was associated with being Caucasian(odds
ratio [OR] = 1.27, 95% conﬁdence interval [CI]: 1.21–1.34),
treatment duration over 12 months (OR = 1.13, 95% CI: 1.07–
1.19), depression (OR = 1.20, 95% CI: 1.14–1.27), impulse
control disorder (OR = 1.53, 95% CI: 1.30–1.79), diabetes mel-
litus (OR = 1.12, 95% CI: 1.05–1.20), cerebrovascular disease
(OR = 1.34, 95% CI: 1.13–1.59). CONCLUSION: The potential
drug-drug interactions should be considered when treating
patients with some antipsychotics, especially during the long-
term maintenance use. Patients with key psychiatric and medical
co-morbidities had a higher risk of receiving potential DDI pairs.
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OBJECTIVE: There is growing awareness of the increased preva-
lence of metabolic abnormalities in patients with schizophrenia.
Thus, the safety and tolerability of atypical antipsychotic (AAP)
medications are important considerations in the choice of agents
to treat severe mental illness. In a systematic review of the pub-
lished literature on AAPs, we explored differences in metabolic
effects between ziprasidone and olanzapine. METHODS: We
identiﬁed 300 published studies of AAPs in schizophrenia,
including head-to-head, placebo-controlled trials and observa-
tional studies. A meta-analysis was performed on the safety and
tolerability of ziprasidone and olanzapine in areas with sufﬁcient
data (i.e., at least three studies for each outcome). Studies were
included in meta-analyses if they provided sample size, mean
change, and measure of variance, or if they reported data to
allow for imputation of these values. We considered changes in
total cholesterol, triglycerides, body weight, QTc interval, and
discontinuation due to adverse events. RESULTS: Of 13 publi-
cations reporting a head-to-head comparison of ziprasidone vs.
olanzapine, four provided data useful for pooled analyses. When
compared to ziprasidone, olanzapine use was associated with
increased total cholesterol (mean difference 20.0 mg/dL [95%
CI 9.8 mg/dL, 30.2 mg/dL]), triglycerides (mean difference
66.6 mg/dL [95% CI 43.6 mg/dL, 89.7 mg/dL]), and body
weight (mean difference 4.97 kg [95% CI 4.1 kg, 5.8 kg]). Mean
daily doses ranged from 112.8 mg to 135.2 mg (ziprasidone) and
from 12.6 mg to 20.5 mg (olanzapine). Mean changes in the QTc
interval and rates of discontinuation due to adverse events were
similar for ziprasidone vs. olanzapine (studies not pooled). Limi-
tations of the study included heterogeneity across the head-to-
head trials: study durations ranged from 6 to 18 months.
CONCLUSION: These results point to clinically important and
statistically signiﬁcant advantages for ziprasidone in metabolic
safety compared with olanzapine. Ziprasidone’s effect on the
QTc interval and tolerability are similar to olanzapine.
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